2024
A Retrospective Study of Patiromer as Adjunct to Insulin Therapy for Acute Hyperkalemia in the Emergency Department
Goriacko P, Golestaneh L, Di Palo K. A Retrospective Study of Patiromer as Adjunct to Insulin Therapy for Acute Hyperkalemia in the Emergency Department. Open Access Emergency Medicine 2024, 16: 305-312. PMID: 39655083, PMCID: PMC11626971, DOI: 10.2147/oaem.s478693.Peer-Reviewed Original ResearchEmergency departmentElectronic health record dataHealth record dataAcute hyperkalemiaClinical benefitAdjunct to insulin therapyPatients treated with insulinDoses of regular insulinAdequate renal functionIntervention groupED settingAdjunct to insulinNet clinical benefitRetrospective cohort studyStudy of patientsPotassium reductionCohort studyRecord dataSecondary outcomesPatiromer groupPrimary outcomeIntravenous doseRenal functionRetrospective studyOverall cohort
2023
Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Winer E, Garcia J, Stone R, Wadleigh M, Luskin M, Stahl M, Chen E, Leonard R, Noyes A, Galinsky I, Deshpande R, Borderies P, O'Neill V, DeAngelo D. Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 2023, 142: 1549. DOI: 10.1182/blood-2023-186598.Peer-Reviewed Original ResearchRelapsed/refractory AMLHypomethylating agentsMetastatic castration-resistant prostate cancerCycles of HMARecommended phase 2 doseRelapsed/Refractory Acute Myeloid LeukemiaAllogeneic bone marrow transplantationCastration-resistant prostate cancerHigh-risk myelodysplastic syndromeNon-small cell lung cancerOral small-molecule inhibitorPhase 2 doseNon-Hodgkin's lymphomaDuration of responseMaximum tolerated doseECOG performance statusT cell responsesAdequate renal functionBone marrow transplantationAdequate liver functionPhase 1 studyCell lung cancerInduction of IL-18Acute myeloid leukemiaActivation of inflammatory cytokines
2013
Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer.
Bamias A, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Koutras A, Pu Y, Galsky M. Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2013, 31: 269-269. DOI: 10.1200/jco.2013.31.6_suppl.269.Peer-Reviewed Original ResearchCisplatin-based chemotherapyCisplatin-based combination chemotherapyMetastatic urothelial carcinomaNo significant differenceElderly patientsVisceral metastasesCombination chemotherapyUrothelial carcinomaBaseline characteristicsCisplatin-based first-line chemotherapySignificant differenceAge groupsPresence of visceral metastasesMetastatic urothelial cancerTreatment-related deathsFirst-line chemotherapyCisplatin-based therapyAdequate renal functionBaseline performance statusFirst-line treatmentProportion of patientsClinical trial enrollmentIndividual patient dataFebrile neutropeniaMedian survivalCisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer
Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urologic Oncology Seminars And Original Investigations 2013, 32: 30.e15-30.e21. PMID: 23428534, DOI: 10.1016/j.urolonc.2012.11.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCisplatinClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCohort StudiesFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisSurvival AnalysisTreatment OutcomeUrologic NeoplasmsUrotheliumConceptsCisplatin-based chemotherapyMetastatic urothelial carcinomaElderly patientsUrothelial carcinomaNo significant differenceCisplatin-based first-line chemotherapyCisplatin-based combination chemotherapyPresence of visceral metastasesMetastatic urothelial cancerTreatment-related deathsFirst-line chemotherapyAdequate renal functionBaseline performance statusFirst-line treatmentSignificant differenceProportion of patientsOlder patient cohortIndividual patient dataFebrile neutropeniaVisceral metastasesCombination chemotherapyMedian survivalIII trialsUrothelial cancerPerformance status
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply